Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence for the clinical and cost effectiveness of cladribine tablets (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Rapidly evolving s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambe, Tosin, Duarte, Rui, Mahon, James, Nevitt, Sarah, Greenhalgh, Janette, Boland, Angela, Beale, Sophie, Kotas, Eleanor, McEntee, Joanne, Pomeroy, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380198/
https://www.ncbi.nlm.nih.gov/pubmed/30328051
http://dx.doi.org/10.1007/s40273-018-0718-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380198/
https://www.ncbi.nlm.nih.gov/pubmed/30328051
http://dx.doi.org/10.1007/s40273-018-0718-2

Ejemplares similares